About Pharmanest Medical need Product candidate SHACT News Contact Does it have to be painful? Each year millions of women are subjected to severe pain in connection with gynecological interventions and childbirth. This is so because the offering of effective and user-friendly drugs for pain relief is extremely limited. Pharmanest is developing new pharmaceuticals based on well- documented active pharmaceutical ingredients in order to offer safe, simple and immediate pain relief. Clinical studies have shown that the company's first product candidate, SHACT, prevents pain and discomfort in women undergoing gynecological interventions without causing any serious side effects. Preparations are currently underway to submit an application for regulatory approval in the EU and conduct phase III trials in the US. Press releases Acerus acquires Canadian rights to novel pain relief product for gynecological procedure from Pharmanest May 29, 2018 More » Helena Jansson appointed as new CEO of Pharmanest May 18, 2018 More » More news » Pharmanest AB Fogdevreten 2A 171 65 SOLNA info@pharmanest.se Orgnr. 556785-1158 © COPYRIGHT PHARMANEST 2018

About Pharmanest Medical need Product candidate SHACT News Contact About Pharmanest History and Founders Management Board Owners About Pharmanest Pharmanest is a Stockholm-based pharmaceutical company specialized in developing products for local pain relief in obstetrics and gynecology. Pharmanest AB is a privately-held pharmaceutical company focused on women’s health. Pharmanest’s lead product, SHACT, is a proprietary short-acting formulation of lidocaine for mucosal pain relief. SHACT’s lead indication is the treatment of pain during intrauterine device (“IUD”) placement. Pharmanest’s initial focus has been to develop and commercialize SHACT for the European and US markets using this as a platform for further penetration of the remaining worldwide markets. In a Phase II trial, SHACT demonstrated statistically and clinically significant pain relief associated with IUD placement. Pharmanest is also developing SHACT in other gynecological indications including hysteroscopy where a feasibility study has been successfully conducted. Pharmanest AB Fogdevreten 2A 171 65 SOLNA info@pharmanest.se Orgnr. 556785-1158 © COPYRIGHT PHARMANEST 2018